BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 27659477)

  • 21. Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.
    Axelsson Raja A; Farhad H; Valente AM; Couce JP; Jefferies JL; Bundgaard H; Zahka K; Lever H; Murphy AM; Ashley E; Day SM; Sherrid MV; Shi L; Bluemke DA; Canter CE; Colan SD; Ho CY
    Circulation; 2018 Aug; 138(8):782-792. PubMed ID: 29622585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extracellular volume fraction in dilated cardiomyopathy patients without obvious late gadolinium enhancement: comparison with healthy control subjects.
    Hong YJ; Park CH; Kim YJ; Hur J; Lee HJ; Hong SR; Suh YJ; Greiser A; Paek MY; Choi BW; Kim TH
    Int J Cardiovasc Imaging; 2015 Jun; 31 Suppl 1():115-22. PubMed ID: 25634119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics.
    Williams LK; Forero JF; Popovic ZB; Phelan D; Delgado D; Rakowski H; Wintersperger BJ; Thavendiranathan P
    J Cardiovasc Magn Reson; 2017 Aug; 19(1):61. PubMed ID: 28784140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Significance of Interstitial Fibrosis on Left Ventricular Function in Hypertensive versus Hypertrophic Cardiomyopathy.
    Jiang M; Wang Z; Su X; Gong X; Pu J; Wu L; Liu C; Yao Q; Kong L; Xu J; He B
    Sci Rep; 2018 Jul; 8(1):9995. PubMed ID: 29968754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myocardial fibrosis evaluated by diffusion-weighted imaging and its relationship to 3D contractile function in patients with hypertrophic cardiomyopathy.
    Wu R; An DA; Shi RY; Chen BH; Jiang M; Bacyinski A; Han TT; Hu J; Xu JR; Wu LM
    J Magn Reson Imaging; 2018 Oct; 48(4):1139-1146. PubMed ID: 29601139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiomic Analysis of Myocardial Native T
    Neisius U; El-Rewaidy H; Nakamori S; Rodriguez J; Manning WJ; Nezafat R
    JACC Cardiovasc Imaging; 2019 Oct; 12(10):1946-1954. PubMed ID: 30660549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy.
    Brouwer WP; Baars EN; Germans T; de Boer K; Beek AM; van der Velden J; van Rossum AC; Hofman MB
    J Cardiovasc Magn Reson; 2014 Apr; 16(1):28. PubMed ID: 24766828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between myocardial hypoxia and fibrosis in hypertrophic cardiomyopathy: analysis by T2* BOLD and T1 mapping MRI.
    Ando K; Nagao M; Watanabe E; Sakai A; Suzuki A; Nakao R; Ishizaki U; Sakai S; Hagiwara N
    Eur Radiol; 2020 Aug; 30(8):4327-4336. PubMed ID: 32211964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
    Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
    Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy.
    Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J
    Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extracellular Volume Associates With Outcomes More Strongly Than Native or Post-Contrast Myocardial T1.
    Treibel TA; Fridman Y; Bering P; Sayeed A; Maanja M; Frojdh F; Niklasson L; Olausson E; Wong TC; Kellman P; Miller CA; Moon JC; Ugander M; Schelbert EB
    JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 1):44-54. PubMed ID: 31103587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Left-ventricular mechanics in children with hypertrophic cardiomyopathy. CMR study.
    Mazurkiewicz Ł; Ziółkowska L; Petryka J; Śpiewak M; Małek Ł; Kubik A; Marczak M; Misko J; Brzezińska-Rajszys G
    Magn Reson Imaging; 2017 Nov; 43():56-65. PubMed ID: 28688952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Myocardial T1 Mapping at 3.0 T to Differentiate Anderson-Fabry Disease from Hypertrophic Cardiomyopathy.
    Karur GR; Robison S; Iwanochko RM; Morel CF; Crean AM; Thavendiranathan P; Nguyen ET; Mathur S; Wasim S; Hanneman K
    Radiology; 2018 Aug; 288(2):398-406. PubMed ID: 29688154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 4D flow MRI and T1 -Mapping: Assessment of altered cardiac hemodynamics and extracellular volume fraction in hypertrophic cardiomyopathy.
    van Ooij P; Allen BD; Contaldi C; Garcia J; Collins J; Carr J; Choudhury L; Bonow RO; Barker AJ; Markl M
    J Magn Reson Imaging; 2016 Jan; 43(1):107-14. PubMed ID: 26227419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue characterisation and myocardial mechanics using cardiac MRI in children with hypertrophic cardiomyopathy.
    Sunthankar S; Parra DA; George-Durrett K; Crum K; Chew JD; Christensen J; Raucci FJ; Xu M; Slaughter JC; Soslow JH
    Cardiol Young; 2019 Dec; 29(12):1459-1467. PubMed ID: 31769372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electrocardiography based prediction of hypertrophy pattern and fibrosis amount in hypertrophic cardiomyopathy: comparative study with cardiac magnetic resonance imaging.
    Park CH; Chung H; Kim Y; Kim JY; Min PK; Lee KA; Yoon YW; Kim TH; Lee BK; Hong BK; Rim SJ; Kwon HM; Choi EY
    Int J Cardiovasc Imaging; 2018 Oct; 34(10):1619-1628. PubMed ID: 29728953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Native T1 mapping and extracellular volume fraction for differentiation of myocardial diseases from normal CMR controls in routine clinical practice.
    Thongsongsang R; Songsangjinda T; Tanapibunpon P; Krittayaphong R
    BMC Cardiovasc Disord; 2021 Jun; 21(1):270. PubMed ID: 34082703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrasonic Assessment of Myocardial Microstructure in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy.
    Hiremath P; Lawler PR; Ho JE; Correia AW; Abbasi SA; Kwong RY; Jerosch-Herold M; Ho CY; Cheng S
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27623770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy--comparison with late enhancement quantification.
    Małek ŁA; Werys K; Kłopotowski M; Śpiewak M; Miłosz-Wieczorek B; Mazurkiewicz Ł; Petryka-Mazurkiewicz J; Marczak M; Witkowski A
    Magn Reson Imaging; 2015 Jul; 33(6):718-24. PubMed ID: 25863138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early detection of myocardial fibrosis in cardiomyopathy in the absence of late enhancement: role of T1 mapping and extracellular volume analysis.
    Gao Y; Wang HP; Liu MX; Gu H; Yuan XS; Biekan J; Wang XM
    Eur Radiol; 2023 Mar; 33(3):1982-1991. PubMed ID: 36241919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.